Alectinib “First of Many Approvals” In ALK+ NSCLC

Commentary
Video

D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.

D. Ross Camidge, MD, PhD, discussed the recent FDA approval of alectinib (Alecensa) as adjuvant treatment for patients with ALK-positive non–small cell lung cancer of which tumors are at least 4 cm or node-positive.1

Camidge, director of the Thoracic Oncology Clinical and Clinical Research programs at the University of Colorado Health, further expressed how this approval may be a stepping stone for the approvals of other agents in this population.

Results for the approval were based on the phase 3 ALINA trial (NCT0346076), which investigated alectinib vs chemotherapy.2 When patients received alectinib, the risk of death or recurrence was reduced by 76% compared with chemotherapy (HR, 0.24; 95% CI, 0.13-0.43; P <.0001). Of note, the disease-free survival rate improved with alectinib when analyzed in an exploratory analysis (HR, 0.22; 95% CI, 0.08-0.58).

The safety and tolerability of alectinib in the ALINA trial was comparable with prior reports of the agent in the metastatic setting.

In the press release of the study, it was noted that the design of alectinib was to help prevent lung cancer recurrence after it has been removed by surgery or to treat those with metastasized tumors.

Of the 257 patients enrolled, 130 patients were given alectinib and 127 were given chemotherapy.

Transcript:

The recent approval of adjuvant alectinib is going to push open a door. People with targetable abnormalities found in the early-stage setting are likely to go on to a well-tolerated treatment to suppress their disease. I don’t know that anyone knows if it’s a cure, or whether we’re just kicking the can down the road. But it’s the beginning of probably multiple approvals in that setting. The key thing is it’s going to be well tolerated. These are [patients] who might be cured. You don’t want them to spend 2 or 3 years on a treatment; that is no fun at all.

References

  1. FDA approves Genentech’s Alecensa as first adjuvant treatment for people with ALK-positive early-stage lung cancer. News release. Genentech. April 18, 2024. Accessed April 29, 2024. https://shorturl.at/zSV29
  2. Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
Related Content